Partner With Us NRI

Rossari Biotech Ltd share Price

Company details

6M Return 39.15%
1Y Return -14.65%
Mkt Cap.(Cr) 4,544.22
Volume 31,638
Div Yield 0.06%
OI Chg %
Volume 31,638

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Specialty chemicals company Rossari Biotech announced Q1FY24 results:

  • Consolidated Q1FY24:
    • Revenue from operations stood at Rs 410.6 crore as against Rs 434.7 crore
    • EBITDA at Rs 57.7 crore as against Rs 57.8 crore
      • EBITDA margin at 14.1% as against 13.3%
    • PAT stood at Rs 29.3 crore as against Rs 28.7 crore
    • EPS (Diluted) stood at Rs 5.28 as against Rs 5.18
  • Standalone Q1FY24:
    • Revenue from operations stood at Rs 258.3 crore as against Rs 233.7 crore
    • EBITDA at Rs 35.1 crore as against Rs 27.1 crore
      • EBITDA margin at 13.6 % as against 11.6%
    • PAT stood at Rs 21.6 crore as against Rs 15.4 crore
    • EPS (Diluted) stood at Rs 3.90 as against Rs 2.78

Commenting on the performance, in a joint statement, Edward Menezes, Promoter & Executive Chairman, and Sunil Chari, Promoter & Managing Director, said, “We have recorded a steady performance during the quarter, demonstrating the resilience and adaptability of our business model amidst a challenging global economic landscape. Our commitment to sustainable and innovative solutions has kept us in a stable position despite the current subdued demand scenario witnessed in the chemical markets.

As a part of its digitisation initiatives, the Company during the quarter went live on SAP S/4 HANA across the Group. For this transformation to a new ERP, the Company had taken about a week’s planned shutdown in April and then about another week for system stabilisation. We are happy to inform you that the entire process happened seamlessly and the system is running smoothly. This planned migration resulted in lower sales in April 2023.

We are delighted to share that during the quarter, we acquired the remaining 16% stake in our subsidiary Tristar Intermediates Private Limited and we are nearing the completion of the acquisition of the remaining stake in Unitop, leading to 100% ownership. Following these strategic moves, our intent to seamlessly integrate both Unitop and Tristar into our operations will drive growth, and enhance overall competitiveness.

R&D continues to be a cornerstone of our growth strategy and will play a pivotal role in the Company’s future roadmap. Our confidence in customised products as a differentiator is backed by our track record in developing unique and innovative solutions for our customers As the market landscape continues to evolve, we see our emphasis on R&D and customised solutions as an important pillar in maintaining consistent growth in a volatile environment.

Despite the macroeconomic challenges, we remain optimistic about the remainder of the year. We firmly believe that our strategic initiatives focused on broadening our customer base, prioritizing higher margin segments, along with our commitment to R&D, particularly in developing new and innovative products, position us favourably for delivering healthy operational and financial performance in the coming years."


Result PDF

View Other Company Results


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Rossari Biotech Ltd Stocks COMPARISION


Equity Capital: 915.17 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 16,852.71 -20,671.82
LAST 3M 52,922.55 -3,405.64
LAST 6M 58,662.39 139,660.95
LAST 12M 135,235.34 165,245.59

Rossari Biotech Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • Rossari Biotech is one of India’s leading chemical and textile manufacturers. The company’s products are used in the paper, construction, pharmaceutical, animal health, and nutrition industries. It has operations in India, Vietnam, Bangladesh, and Mauritius. The company, founded in 2003, operates two research and development facilities in India. It is headquartered in Mumbai, India. 

    On 22 January 2023, the market capitalisation of the company was Rs 3,926.82 crore. It reported a total revenue of Rs 240.9 crore at the end of the second quarter of the financial year 2022-2023. The company is listed on the Bombay Stock Exchange with the code 543213 and on the National Stock Exchange under the code ROSSARI.   

    Rossari Biotech has a diversified shareholding pattern, with promoters holding approximately 68.44% of the company. The public has a stake of 8.87% in the company. FIIs hold a stake of 8.61% in the company, while DIIs hold 14.08%. The shareholding pattern of the company has remained largely stable over the past year.

    Edward Menezes is the current chairman of the company. Other directors of the company include Sunil Chari, Aseem Dhru, Goutam Bhattacharya, Meher Castelino, Robin Banerjee, and Sharabh Pachory. The chief financial officer of Rossari Biotech is Ketan Sablok. The company’s auditors are Deloitte Haskins & Sells LLP.  

    On 22 January 2023, Rossari Biotech’s share price was Rs 710.85 on the BSE and Rs 710.35 on the NSE. The company’s 52-week-high was Rs 1,283.15, while the 52-week-low was Rs 648.00. Its three-month return to investors was -24.6%, while its one-year return was -43.3%.

    The company’s trailing twelve-month (TTM) revenue was Rs 1,482.97 crore as of 31 December 2022. At the same time, the company had a net profit of Rs 97.70 crore. The company’s P/E TTM was 39.4. The ROE of the company was 16.1, while the ROCE of the company was 22.7.

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code: 07730), BSE Ltd (Member Code: 103) and Member of Multi Commodity Exchange of India Ltd.(Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Ms. Mamta Shetty, Contact number: 022-40701022, E-mail address: complianceofficer@icicisecurities.com. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Such representations are not indicative of future results. The securities quoted are exemplary and are not recommendatory. Investors should consult their financial advisers if in doubt about whether the product is suitable for them. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Registered Address

201 A-B 2nd Floor LBS Marg, Akruti Corporate Park Kanjur(W, Mumbai, Maharashtra, 400079

Tel : 91-22-6123 3800
Email : cs:rossarimail.com
Website : http://www.rossari.com

Link Intime India Pvt Ltd

AGM Date (Month) : Jul
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 543213
Book Closure Date (Month) :
BSE Group : A
ISIN : INE02A801020

FAQ’s on Rossari Biotech Ltd Shares

You can buy Rossari Biotech Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Rossari Biotech Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Oct 03, 2023 03:57 PM the closing price of Rossari Biotech Ltd was ₹ 823.90.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Oct 03, 2023 03:57 PM, the market cap of Rossari Biotech Ltd stood at ₹ 4,544.22.

The latest PE ratio of Rossari Biotech Ltd as of Oct 03, 2023 03:57 PM is 42.19

The latest PB ratio of Rossari Biotech Ltd as of Oct 03, 2023 03:57 PM is 0.20

The 52-week high of Rossari Biotech Ltd is ₹ 957.00 while the 52-week low is ₹ 536.35

Download Our App

market app
market app